How White was paid
$1.3M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Other | Total |
|---|---|---|---|---|---|
| Marvin L. WhitePresident and Chief Executive Officer | $630,269 | $400,000 | $236,555 | $10,500 | $1,277,403 |
| Jeffrey G. LamotheExecutive Vice President and Chief Operating Officer | $536,008 | $300,000 | $173,664 | $10,500 | $1,020,205 |
| SoYoung KwonSenior Vice President, General Counsel, Business Development and Corporate Affairs | $499,221 | $250,000 | $144,720 | $10,500 | $904,464 |
What changed and why
- $400K$400,000 one-time supplemental cash payment was awarded to CEO Marvin White in August 2025.
- $237K$236,555 in equity awards represented the CEO’s 2025 reported equity compensation.
- 96%96% of the corporate performance weighting factor and 100% of the individual factor determined 2025 bonus payouts.
- 70%70% was the CEO’s adjusted 2025 target bonus percentage, up from 55% before the August adjustment.
- April 1, 2026 marked White’s retirement as CEO and Jeffrey Lamothe’s appointment as CEO.
- The Company adjusted executive compensation toward the 75th percentile of public-company peers.
Other Aptevo Therapeutics proxy statements
- 2025 proxy statement
Marvin L. White paid $906,020 (+4% on the year).
Filed Jul 03, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.